Scynexis Inc SCYX

NAS: SCYX | ISIN: US8112921015 8/06/2023

2,590 USD (+1,97%)

(+1,97%) 8/06/2023

Toon enkel gratis nieuws

30 september 2021 · Antimicrobials Working Group Highlights Member Company Participation at IDWeek 2021 · Persbericht

5 augustus 2021 · Acurx Pharmaceuticals Joins the Antimicrobials Working Group · Persbericht

8 juni 2021 · Crestone Joins Antimicrobials Working Group · Persbericht

2 maart 2021 · SCYNEXIS Announces Positive Results from Interim Analyses of Ongoing Phase 3 Studies (FURI and CARES), Demonstrating Oral Ibrexafungerp's Ability to Treat Severe Fungal Infections in the Hospital Setting · Persbericht

25 februari 2021 · SCYNEXIS to Participate in Maxim Group’s Late Stage Innovations in Women’s Health Virtual Event · Persbericht

23 februari 2021 · SCYNEXIS and Amplity Health Announce Agreement to Support the Anticipated U.S. Commercialization of BrexafemmeTM (Ibrexafungerp) for Vaginal Yeast Infections · Persbericht

17 februari 2021 · UTILITY Therapeutics Joins Antimicrobials Working Group · Persbericht

17 februari 2021 · SCYNEXIS Announces Licensing Agreement and Strategic Partnership with Hansoh Pharma for Rights to Ibrexafungerp in Greater China · Persbericht

Mijn selecties

Je selectie is nog leeg.

Voeg nu effecten toe